Thermo Fisher Details Executive Pay Changes After Low Say-on-Pay Vote
Summary
Thermo Fisher Scientific filed supplemental proxy materials to explain its executive compensation program and detail significant changes for 2026, following low shareholder support for its 2025 executive pay proposal.
Key Events
-
Shareholder Vote Response
The company provided supplemental information to shareholders regarding Proposal 2 (Advisory Vote to Approve Executive Compensation) for its upcoming May 20, 2026, annual meeting, directly addressing the low 36% shareholder support received for its 2025 executive compensation proposal.
-
2026 Compensation Program Changes
Thermo Fisher announced meaningful changes to its executive compensation program for 2026, including a shift to a three-year performance design for PRSUs, revised metrics (adjusted EPS, relative TSR, adjusted ROIC modifier), increased PRSU weighting, and a commitment to avoid one-time equity grants except in extraordinary circumstances.
-
Accountability Demonstrated
The Compensation Committee highlighted that 2025 annual incentive and PRSU payouts were below target, with one PRSU cycle paying out at 0% for the CEO and most named executive officers, demonstrating that compensation outcomes are tied to business performance.
-
CEO Retention Grant Clarification
The filing provided a detailed explanation of the 2025 CEO retention grant, emphasizing its purpose for leadership continuity, its five-year cliff vesting, and its performance alignment through relative TSR against the S&P 500, with a cap for negative absolute TSR.
Analysis
This filing is a direct response to significant shareholder dissent regarding executive compensation, as evidenced by the low 36% support for the 2025 proposal. The detailed explanation of past pay outcomes and the commitment to "meaningful 2026 program changes" demonstrate the company's responsiveness to investor feedback. These governance improvements aim to better align executive incentives with long-term shareholder value and could improve investor confidence in the company's compensation practices.
At the time of this filing, TMO was trading at $468.50 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $172.8B. The 52-week trading range was $385.46 to $643.99. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.